← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	1,047	+8	+0.8%	$50.7B
2	2 Thermo Fisher Scientific TMO $249B	1,025	+18	+2%	$49.3B
3	3 Novartis NVS $279B	876	-51	-6%	$17.3B
4	4 Agilent Technologies A $49.1B	558	+5	+0.9%	$11.1B
5	5 Illumina ILMN $41B	552	-9	-2%	$22.7B
6	6 Regeneron Pharmaceuticals REGN $80.1B	550	-27	-5%	$26.2B
7	7 Revvity RVTY $17B	330	+5	+2%	$4.91B
8	8 Ionis Pharmaceuticals IONS $7.1B	315	-20	-6%	$4.26B
9	9 Charles River Laboratories CRL $14.4B	264	-4	-1%	$3.57B
10	10 Alnylam Pharmaceuticals ALNY $30B	255	-6	-2%	$4.45B
11	11 Myriad Genetics MYGN $397M	234	+1	+0.4%	$3.07B
12	12 Bruker BRKR $8.47B	228	+38	+20%	$3.05B
13	13 Precigen PGEN $2.64B	191	+11	+6%	$3.42B
14	14 DELISTED bluebird bio BLUE	187	-6	-3%	$1.72B
15	15 DELISTED CATALENT, INC. CTLT	174	-14	-7%	$3.37B
16	ISEE 16 DELISTED IVERIC bio, Inc. Common Stock ISEE	162	+10	+7%	$1.37B
17	17 Ultragenyx Pharmaceutical RARE $1.47B	162	-10	-6%	$2.37B
18	18 Azenta AZTA $1.63B	146	+1	+0.7%	$660M
19	19 DELISTED SANGAMO THERAPEUTICS INC SGMO	143	+2	+1%	$292M
20	20 Sarepta Therapeutics SRPT $1.78B	132	-19	-13%	$686M
21	21 Pacific Biosciences PACB $619M	130	+11	+9%	$491M
22	22 PTC Therapeutics PTCT $4.98B	119	-22	-16%	$190M
23	23 Standard BioTools LAB $248M	100	-6	-6%	$230M
24	AGTC 24 DELISTED Applied Genetic Technologies Corporation AGTC	90	+2	+2%	$148M
25	25 DELISTED Adverum Biotechnologies ADVM	82	+6	+8%	$80.1M